Novo Nordisk's Top Scientist Just Said the Quiet Part Out Loud

Retatrutide takes a completely different approach. It's a single molecule that activates three receptors at once: GLP-1, GIP, and glucagon. The first two handle appetite suppression, similar to what tirzepatide (Zepbound) does. But the glucagon piece is the wild card. Glucagon activation may actually increase the body's energy expenditure, essentially turning up the metabolic furnace. CagriSema makes you eat less; retatrutide does that and potentially makes your body burn more.

It's the difference between cutting your spending and cutting your spending while also getting a raise.

Novo's Not Waving the White Flag (Yet)

Lange was careful to frame his comments as a "not yet" rather than a "never." He pointed to the ongoing REDEFINE 1 study with optimized dosing, which Novo believes will unlock even higher weight loss by refining how patients ramp up to full dose. The argument: CagriSema hasn't shown its full potential because the titration schedule (the gradual dose increases designed to limit nausea) wasn't aggressive enough in earlier trials.

Novo also used ADA to showcase CagriSema's diabetes data from the REIMAGINE program, and those results looked genuinely strong. In the REIMAGINE 2 trial, CagriSema beat semaglutide head-to-head in patients with type 2 diabetes: 14.2% weight loss versus 10.2%, with better blood sugar control to boot. About 43% of CagriSema patients lost 15% or more of their body weight.

The diabetes story is real. The question is whether "we beat our own drug" is a compelling enough pitch when Lilly is posting surgery-level results.

Wall Street Has Already Picked a Side

Investors didn't wait for the jury. Novo's stock had already fallen roughly 35-36% over the prior year before the ADA meeting, and shares dropped another 15-16% after the earlier REDEFINE-4 head-to-head trial showed CagriSema couldn't match tirzepatide (Lilly's already-approved Zepbound). In that trial, CagriSema delivered 23% weight loss versus tirzepatide's 25.5% at 84 weeks and failed to prove non-inferiority, which is the statistical equivalent of admitting the other drug is better.

Lilly's stock, meanwhile, climbed 3-5% on those same results.

J.P. Morgan analyst Chris Schott said the data "confirms Zepbound as a clear market leader for now" and projected Lilly would enjoy extended market share growth past 2026. Barclays analyst James Gordon described CagriSema's uptake as an "uphill battle" versus a more effective, better-tolerated incumbent, leaving Novo with little leverage aside from pricing. Bernstein warned that retatrutide's arrival on a similar timeline would squeeze Novo even further.

Not everyone is bearish on Novo, though. Morningstar argued the stock looks undervalued after the selloff, contending the market is underestimating Novo's long-term competitiveness in GLP-1 therapies. It's a classic value-versus-momentum debate.

The Bigger Picture: Obesity's Arms Race Is Just Getting Started

Step back and the real story becomes clear. We've gone from a world where losing 15% of your body weight on a drug was groundbreaking (that was semaglutide's moment) to one where 25-30% weight loss is the new bar. Retatrutide is pushing pharmacologic weight loss into territory that was previously reserved for the operating room.

For patients, this is extraordinary news. For Novo Nordisk, it's an existential strategic challenge. CagriSema will almost certainly get approved; it's already been submitted to the FDA. It will sell billions. But "good enough" is a dangerous position in a market that's moving this fast.

Lange's candor at ADA was refreshing and unusual. Pharma executives almost never concede competitive ground in public. The fact that he did suggests Novo understands the scoreboard. The question now is whether the REDEFINE 1 optimized dosing data can change it.

Because right now, the jury isn't so much "still out" as it is leaning heavily toward the other side of the courtroom.

Sanofi's Plan B Just Lost Its Plan B

Sanofi just halted another late-stage trial, and it's not the first pipeline disappointment this year. With Dupixent's patents expiring around 2031 and its top successor underwhelming Wall Street, the pressure to find a Plan D is getting very real.